PF-Atlas › Clinical Trials › NCT05513950
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody in Patients With IPF .
CHF10067 starting dose -- 1000mg · Phase 1
Registry ID
NCT05513950
Phase
Phase 1
Status
Completed
Drug / intervention
CHF10067 starting dose -- 1000mg (Cohort A)
Sponsor
Chiesi Farmaceutici S.p.A.
Start
2023-01-25
Enrollment
52
Locations
9
About this trial
Assess the safety of CHF10067 (study drug) and any side effects that might be associated with it. The study also evaluated how much of the study drug gets into the bloodstream and how long the body takes to remove it. The body's immune response to the study drug was evaluated. Chiesi conducted this study in patients affected by idiopathic pulmonary fibrosis (IPF, a progressive and chronic lung disease). Chiesi performed this study to establish the drug doses that would be suitable for future studies (a dose finding study).
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05513950 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.